Our people

Dr David Good

Senior Lecturer, Anatomy and Pre-clinical Science
School of Allied Health

Areas of expertise: biomedical research

Phone: 3623 7657

Email: David.good@acu.edu.au

Location: ACU Brisbane Campus

ORCID ID: 0000-0002-8758-2124

I have worked in the field of biomedical research since commencing post-graduate studies in 1997. Since then, I have been involved in a number of different internationally recognised research projects ranging from obesity to cancer. In 2008 helped I established the Division of Molecular and Gene Therapies within the Griffith Institute for Health and Medical Research. I was subsequently appointed the Head of the Clinical Research Unit. Some of the projects I am currently involved in include, genetics of type 2 diabetes, research into solid tumours (lung cancer, prostate, breast and colorectal cancer) and Chinese traditional medicines. In early 2009, I help establish a collaborative link with a number of international universities and more recently I have been responsible for establishing links with industry partners.

Over the course of my career I have had the opportunity to teach medical students at the University of Queensland. Since 2008 I was the course convenor (lecturer-in-charge) for anatomy and physiology at Griffith University. In this role I received many student nominations for Teaching Excellence Awards. In 2010, I also received a Commendation for outstanding performance in enhancing the quality of student learning.

I am currently the senior lecturer for Anatomy and Pre-clinical Sciences in the School of Allied Health at the Australian Catholic University.

Download curriculum vitae

Select publications

• Yang B, Good D, Mosaiab T, Liu W, Ni G, Kaur J, Liu X, Jessop C, Yang L, Fadhil R, Yi Z, Wei MQ. Significance of LL-37 on Immunomodulation and Disease Outcome. Biomed Res Int. 2020 May 16;2020:8349712.
• Ni G, Wang Y, Good D, Yuan J, Pan X, Wei J, Liu X, Wei MQ. The Dosage of the Derivative of Clostridium Ghonii (DCG) Spores Dictates Whether an IFNγ/IL-9 or a Strong IFNγ Response Is Elicited in TC-1 Tumour Bearing Mice. Biomed Res Int. 2019 Apr 28;2019:1395138.
• Jiang S, Good D, Wei MQ. Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants. Int J Mol Sci. 2019 Jul 11;20(14):3403.
• Liu W, Yang B, Yang L, Kaur J, Jessop C, Fadhil R, Good D, Ni G, Liu X, Mosaiab T, Yi Z, Wei MQ. Therapeutic Effects of Ten Commonly Used Chinese Herbs and Their Bioactive Compounds on Cancers. Evid Based Complement Alternat Med. 2019 Sep 15;2019:6057837.
• Umer B, Good D, Anné J, Duan W, Wei M. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. Journal of toxicology. 2012:862764. DOI: 10.1155/2012/862764
• Wei MQ, Mengesha A, Good D, Anné J. Bacterial targeted tumour therapy - dawn of a new era. Cancer Letters. 2008; 259:16 - 27.
• D. Good, John Cardinal, Robert S Ware, Lisa Marks, Janine B Kesting, Lionel CK Chan, Joanne TE Shaw. Susceptibility to insulin resistance in indigenous Australians may be down stream of resistin. International Journal of Diabetes and Metabolism. 2008 16: 1-6 .
• Good DA, Busfield F, Fletcher B, Lovelock PK, Duffy D, Kesting J, Andersen J, Shaw J.T.E. Identification of SQSTM1/p62 mutations in familial Paget's disease in Australian pedigrees. Bone. 2004 Jul;35(1):277 - 282
• Good DA, Busfield F, Fletcher BH, Duffy DL, Kesting JB, Andersen J, Shaw JT. Linkage of Paget's disease of bone to a novel region on human chromosome 18q23. American Journal of Human Genetics. 2002 Feb; 70(2):517-25.
• Busfield F, Duffy DL, Kesting JB, Walker SM, Lovelock PK, Good D, Tate H, Watego D, Marczak M, Hayman N, Shaw JT. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. American Journal of Human Genetics. 2002 Feb; 70(2):349-57.

Projects

I have worked on a number of health-related research topics that have covered many different clinical conditions and biological systems. These topics have included obesity, Paget's disease of bone, the implication of Chlamydia pneumoniae infection in the etiology of atherosclerosis, hypertension, solid tumours and type 2 diabetes in both a community-based education program as well as a laboratory based project.

My current research projects at Division of Molecular and Gene Therapies include trying to produce more effective safer treatments for solid tumours. Solid tumours account for 90% of all cancers and gene therapy represents a potential new modality for their treatment.

Previous research projects include:

1. The genetics of type 2 diabetes in an Indigenous Australian community. In this project we have been searching for genes responsible for type 2 diabetes. In this project I was successful in the identification of a novel gene responsible for this condition. In this project we has also looked at both current and emerging biochemical markers for both type 2 diabetes and cardiovascular diseases and looked at any correlation with either molecular markers or disease state.
2. Along with the genetic work in the Indigenous Australian community, we implemented a lifestyle intervention program in order to educate these people on how to manage their diabetes, decrease their weight and subsequently reduce the burden of type 2 diabetes. We have also assayed a number of important biochemical markers for cardiovascular disease and studied the correlation between them and molecular markers or disease state.

Accolades and Awards

• 2016 Preclinical and clinical trials of clostridial oncolytic cancer therapy. Jinan Government, China. 4 million Yuan.
• 2010 Nomination for Griffith University Excellence in Teaching award.
• 2009 Commendation for outstanding performance in enhancing the quality of student learning. This is recognition of my excellent teaching during 2009 based on student evaluations.
• 2009 Nomination for Griffith University Excellence in Teaching award.
• 2008 Nomination for Griffith University Excellence in Teaching award.